InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
Go back to InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos| InferX Corporation (NASDAQ: IFRX) | Delayed: 2.22 -0.01 (0.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.23 | 52 Week High | $0.05 | |||
| Open | $2.21 | 52 Week Low | $0.00 | |||
| Day High | $2.38 | P/E | N/A | |||
| Day Low | $2.16 | EPS | $0.00 | |||
| Volume | 393,944 | |||||
